epilepsy


A machine learning autism classification based on logistic regression analysis

#artificialintelligence

Autistic Spectrum Disorder (ASD) is a neurodevelopmental condition associated with significant healthcare costs; early diagnosis could substantially reduce these. The economic impact of autism reveals an urgent need for the development of easily implemented and effective screening methods. Therefore, time-efficient ASD screening is imperative to help health professionals and to inform individuals whether they should pursue formal clinical diagnosis. Presently, very limited autism datasets associated with screening are available and most of them are genetic in nature. We propose new machine learning framework related to autism screening of adults and adolescents that contain vital features and perform predictive analysis using logistic regression to reveal important information related to autism screening.


New AI Model Shortens Drug Discovery to Days, Not Years

#artificialintelligence

Biotechnology, pharmaceutical, and life sciences industries are where applied artificial intelligence (AI) can greatly accelerate innovation and shorten the product development life-cycle. Developing a drug typically takes 10 to 15 years on average, with only approximately 12 percent of drugs in clinical trials ultimately gaining U.S. Food and Drug Administration (FDA) approval. In an AI milestone in life sciences, Insilico Medicine announced a new machine learning tool for drug discovery that can generate a novel molecule in days instead of years and published their findings in Nature Biotechnology on September 2, 2019. Insilico Medicine is a venture-backed start-up with multiple investors that include WuXi AppTec, Juvenescence, Peter Diamandis' BOLD Capital Partners, and Pavilion Capital. Led by CEO and Founder Alex Zhavoronkov, the company's mission is to extend longevity by applied AI solutions for drug discovery and aging research.


New AI Model Shortens Drug Discovery to Days, Not Years

#artificialintelligence

Biotechnology, pharmaceutical, and life sciences industries are where applied artificial intelligence (AI) can greatly accelerate innovation and shorten the product development life-cycle. Developing a drug typically takes 10 to 15 years on average, with only approximately 12 percent of drugs in clinical trials ultimately gaining U.S. Food and Drug Administration (FDA) approval. In an AI milestone in life sciences, Insilico Medicine announced a new machine learning tool for drug discovery that can generate a novel molecule in days instead of years and published their findings in Nature Biotechnology on September 2, 2019. Insilico Medicine is a venture-backed start-up with multiple investors that include WuXi AppTec, Juvenescence, Peter Diamandis' BOLD Capital Partners, and Pavilion Capital. Led by CEO and Founder Alex Zhavoronkov, the company's mission is to extend longevity by applied AI solutions for drug discovery and aging research.


Newsroom

#artificialintelligence

Nashua, N.H. – September 10, 2019 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced the results of its reader study for ProFound AI fo... Continue reading


Marion Mulder on LinkedIn: "Hope to see you there! Dont forget to register ;-) #women #leadership #AI #STEM #tech"

#artificialintelligence

Future Frontiers - xX Edition in Eindhoven: Only 3 weeks to sign up for this great event. Learn about AI ethics, diverse leadership, controlled fabrication and integration of 1-D and 2-D nano-materials on an industrial scale.


Brain implants could leak people's THOUGHTS to governments or companies, scientists warn

Daily Mail - Science & tech

Pioneering brain implants currently used for stroke or epilepsy patients could be used to track people's thoughts - and relay them back to governments or companies. That's the Orwellian warning from scientists at the Royal Society, who say reading chips pose a huge privacy issue. The society has urged the government to launch an inquiry and protect human rights against the commercial development of neural interface software. It comes after both Elon Musk and Mark Zuckerberg expressed plans to incorporate the technology into their businesses. This would allow users to interact with augmented reality environments using just their brain - no keyboards, touchscreens or hand gestures required.


Linking Genes and Diseases Using AI

#artificialintelligence

Artificial intelligence (AI) is being harnessed by researchers to track down genes that cause disease. A KAUST team is taking a creative, combined deep learning approach that uses data from multiple sources to teach algorithms how to find patterns between genes and diseases. Machine learning uses algorithms and statistical models to identify patterns and associations among data to solve specific problems. By inputting enough known data, like tagged images of "Jack," the system can eventually learn to suggest other nontagged images that include Jack. Researchers are using this application of AI to find genes that cause diseases.


New AI Model Shortens Drug Discovery to Days, Not Years

#artificialintelligence

Biotechnology, pharmaceutical, and life sciences industries are where applied artificial intelligence (AI) can greatly accelerate innovation and shorten the product development life-cycle. Developing a drug typically takes 10 to 15 years on average, with only approximately 12 percent of drugs in clinical trials ultimately gaining U.S. Food and Drug Administration (FDA) approval. In an AI milestone in life sciences, Insilico Medicine announced a new machine learning tool for drug discovery that can generate a novel molecule in days instead of years and published their findings in Nature Biotechnology on September 2, 2019. Insilico Medicine is a venture-backed start-up with multiple investors that include WuXi AppTec, Juvenescence, Peter Diamandis' BOLD Capital Partners, and Pavilion Capital. Led by CEO and Founder Alex Zhavoronkov, the company's mission is to extend longevity by applied AI solutions for drug discovery and aging research.


New AI Model Shortens Drug Discovery to Days, Not Years

#artificialintelligence

Biotechnology, pharmaceutical and life sciences industries are where applied artificial intelligence (AI) can greatly accelerate innovation and shorten the product development life-cycle. Developing a drug typically takes 10 to 15 years on average, with only approximately 12 percent of drugs in clinical trials ultimately gaining U.S. Food and Drug Administration (FDA) approval. In an AI milestone in life sciences, Insilico Medicine announced a new machine learning tool for drug discovery that can generate a novel molecule in days instead of years, and published their findings in Nature Biotechnology on September 2, 2019. Insilico Medicine is a venture-backed start-up with multiple investors that include WuXi AppTec, Juvenescence, Peter Diamandis' BOLD Capital Partners, and Pavilion Capital. Led by CEO and Founder Alex Zhavoronkov, the company's mission is to extend longevity by applied AI solutions for drug discovery and aging research.


Artificial intelligence learns complex patterns between genes and diseases

#artificialintelligence

Artificial intelligence (AI) is being harnessed by researchers to track down genes that cause disease. A KAUST team is taking a creative, combined deep learning approach that uses data from multiple sources to teach algorithms how to find patterns between genes and diseases. Machine learning uses algorithms and statistical models to identify patterns and associations among data to solve specific problems. By inputting enough known data, like tagged images of "Jack," the system can eventually learn to suggest other nontagged images that include Jack. Researchers are using this application of AI to find genes that cause diseases.